Litcius/Paper detail

LBA42 Distant metastasis-free survival of neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable, macroscopic stage III melanoma: The NADINA trial

M.W. Lucas, A.M. Menzies, Marta López‐Yurda, Richard A. Scolyer, B. van de Wiel, R.P.M. Saw, W. Van Houdt, Nigel G. Maher, A. Torres Acosta, M. Boers-Sonderen, G. Hospers, M.S. Carlino, Jan Willem de Groot, E. Kapiteijn, K. Suijkerbuijk, P. Rutkowski, Shahneen Sandhu, Astrid A.M. van der Veldt, G.V. Long, C.U. Blank

2024Annals of Oncology12 citationsDOIOpen Access PDF

Topics & Concepts

MedicineNivolumabIpilimumabOncologyAdjuvantInternal medicineMelanomaStage (stratigraphy)Neoadjuvant therapyImmunotherapyCancerCancer researchBiologyBreast cancerPaleontologyCancer Immunotherapy and BiomarkersMelanoma and MAPK PathwaysCutaneous Melanoma Detection and Management
LBA42 Distant metastasis-free survival of neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable, macroscopic stage III melanoma: The NADINA trial | Litcius